randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
Status:
Completed
Trial end date:
2018-04-11
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, actively controlled, double-blind study with prospective data
collection was to assess differences between sacubitril/valsartan versus enalapril in
increasing exercise capacity and non-sedentary physical activity in HFrEF patients. Physical
activity was assessed by the 6 minute walk test, and daily physical activity was continuously
measured by means of a wrist-worn accelerometry device from 2 weeks before until 12 weeks
after start of study therapy (sacubitril/valsartan or enalapril).
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Enalapril Enalaprilat LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan